India distribution disruption from GST change
The three-tier distribution model caused a one-time 87% drop in primary sales due to inventory destocking; similar regulatory changes could recur.
medium · management_commentary
Glenmark Pharmaceuticals Limited — Q2 FY26
Glenmark's Q2 FY26 consolidated revenue surged 76% YoY to ₹6,047 crore, driven by the ISB 2001 out-licensing deal which contributed ₹4,466 crore in North America.
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Recurring write-offs and litigation costs
Analyst highlighted past write-offs (Mondro, Zeta, antitrust) totaling significant amounts; management acknowledged but offered limited assurance on future controls.
high · analyst_questionIGI pipeline execution risk
ISB 2301 and three other multi-specific programs are preclinical; failure to advance or partner could impair value.
medium · data_observationGeopolitical uncertainty in emerging markets
EM revenue declined 6.5% due to geopolitical issues in Latin America and West Africa; recovery uncertain.
medium · management_commentary